Characteristics | Patients (N=116) |
Age | |
<65 years, n (%) | 22 (19.0) |
≥65 years, n (%) | 94 (81.0) |
Median (range), years | 74 (41–93) |
Sex, n (%) | |
Male | 81 (69.8) |
Female | 35 (30.2) |
ECOG PS, n (%) | |
0 | 72 (62.1) |
1 | 44 (37.9) |
Geographic region, n (%) | |
North America | 29 (25.0) |
Western Europe | 75 (64.7) |
Australia | 9 (7.8) |
Asia | 3 (2.6) |
Time since initial diagnosis, median (range), months | 10.6 (0.7–120.9) |
Time since diagnosis of metastatic disease, median (range), months | 2.2 (0.4–49.6) |
Site of primary tumor, n (%) | |
Skin | 104 (89.7) |
Lymph node | 1 (0.9) |
Not reported | 11 (9.5) |
Visceral metastases at baseline, n (%) | |
Present | 79 (68.1) |
Absent | 35 (30.2) |
Not reported | 2 (1.7) |
PD-L1 status, n (%)* | |
Positive | 21 (18.1) |
Negative | 87 (75.0) |
Not evaluable | 8 (6.9) |
MCPyV status, n (%)† | |
Positive | 70 (60.3) |
Negative | 37 (31.9) |
Not evaluable | 9 (7.8) |
Prior anticancer drug therapy, n (%) | |
No | 110 (94.8) |
Yes | 6 (5.2) |
*PD-L1+ status was defined as expression in ≥1% of tumor cells, assessed using a Dako PD-L1 73-10 IHC assay.
†Assessed by IHC.
ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; MCPyV, Merkel cell polyomavirus; PD-L1, programmed death ligand 1.